Citius Oncology Welcomes Jonathan Peri to Its Board of Directors to Enhance Growth Strategy

Citius Oncology Expands Board with New Appointments

Citius Oncology, Inc. (Nasdaq: CTOR), a biopharmaceutical company dedicated to oncology, is making significant strides in its governance by appointing Jonathan Peri, Ph.D., J.D., as an independent director of its Board. This development was announced on August 12, 2026, and will take effect from August 10, 2026. With this addition, the board now consists of nine members, underscoring the company's commitment to strengthening its oversight and strategic direction.

Dr. Jonathan Peri brings an impressive portfolio of experience, having spent over thirty years in leadership roles across various sectors, including higher education and financial services. He currently holds the position of President at Manor College and has previously served as Vice President and General Counsel at Neumann University, managing legal affairs for the institution. His experience also extends to governance roles in educational and nonprofit organizations and advisory positions, notably as lead advisory board director of First State Bank in Texas from 2021 to 2024.

The Board's decision to bring Dr. Peri on board was unanimous, reflecting the confidence in his capabilities to guide Citius Oncology as it pushes forward with its initiatives, particularly the commercial launch of their oncology treatment, LYMPHIR®. Leonard Mazur, the Chairman and CEO of Citius Oncology, expressed enthusiasm about Dr. Peri’s appointment, stating that his background in leading complex organizations and his strategic approach will be pivotal as the company strives to enhance shareholder value and meet patient needs.

Dr. Peri himself expressed his excitement about joining the Board at such a critical juncture, highlighting Citius Oncology's focus on addressing the unmet medical needs in the treatment of cutaneous T-cell lymphoma (CTCL). He looks forward to contributing to the strategic oversight as the company continues to innovate in oncology therapies.

Dr. Peri’s credentials are extensive; he earned his undergraduate degree from Villanova University, graduated with a law degree from Widener University, and obtained a doctorate in Organizational Leadership from Eastern University. Additionally, he holds a certificate in Management and Leadership in Education from Harvard University. His role as a Commissioner of the Middle States Commission on Higher Education further showcases his commitment to educational governance and oversight.

With Dr. Peri’s addition to the Board, Citius Oncology aims to enhance its governance framework and advance its mission of delivering cutting-edge oncology treatments. The company successfully launched LYMPHIR, which is FDA-approved for adults facing relapsed or refractory Stage I–III CTCL after previous systemic therapies. The CTCL market presents significant opportunity, valued at over $400 million and showing promising growth due to a lack of effective existing treatments. Citius Oncology’s strong intellectual property rights covering various aspects of their innovative therapies position them favorably in the competitive landscape.

In conclusion, the appointment of Jonathan Peri to Citius Oncology’s Board represents a strategic enhancement to the company's leadership. As Citius continues to innovate and develop crucial treatments for complex cancers, the insights and experience Dr. Peri brings will undoubtedly play a vital role in navigating the challenges ahead, ensuring that the company meets its objectives while positively impacting patients’ lives.

For more information about Citius Oncology and its developments, please visit Citius Oncology Website.